Cristin Rothfuss Sarepta Therapeutics, Inc. (SRPT) insider trading activity

Cristin Rothfuss is EVP, General Counsel of Sarepta Therapeutics, Inc.. Currently has a direct ownership of 139,756 shares of SRPT, which is worth approximately $2.63 Million. The most recent transaction as insider was on Nov 28, 2025, when has been sold 229 shares (Common Stock) at a price of $21.12 per share, resulting in proceeds of $4,836. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 140K

0.16% 3M change

911.48% 12M change

Total Value Held $2.63 Million

Cristin Rothfuss Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 28 2025	SELL Payment of exercise price or tax liability	$4,836 $21.12 p/Share	229 Reduced 0.16%	139,756 Common Stock
Sep 03 2025	BUY Grant, award, or other acquisition	-	118,875 Added 45.92%	139,985 Common Stock
Mar 10 2025	SELL Payment of exercise price or tax liability	$49,163 $100.13 p/Share	491 Reduced 3.68%	12,834 Common Stock
Mar 10 2025	BUY Grant, award, or other acquisition	-	8,276 Added 28.16%	21,110 Common Stock
Mar 07 2025	SELL Payment of exercise price or tax liability	$153,268 $103.7 p/Share	1,478 Reduced 11.09%	11,847 Common Stock
Mar 04 2025	SELL Payment of exercise price or tax liability	$59,182 $101.34 p/Share	584 Reduced 4.2%	13,325 Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$40,574 $103.77 p/Share	391 Reduced 2.79%	13,621 Common Stock

Nov 26 2024	BUY Grant, award, or other acquisition	-	2,000 Added 12.64%	13,817 Common Stock

Cristin Rothfuss

EVP, General Counsel

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Value

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT

Account